{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T06:43:19Z","timestamp":1794638599520,"version":"4.9.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T00:00:00Z","timestamp":1568764800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T00:00:00Z","timestamp":1568764800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:p>The introduction of next-generation sequencing has resulted in testing multiple genes simultaneously to identify inherited pathogenic variants (PVs) in cancer susceptibility genes. PVs with low minor allele frequencies (MAFs) (&lt;\u200925\u201335%) are highlighted on germline genetic test reports. In this review, we focus on the challenges of interpreting PVs with low MAF in breast cancer patients undergoing germline testing and the implications for management.<\/jats:p>\n              <jats:p>The clinical implications of a germline PV are substantial. For PV carriers in high-penetrance genes like <jats:italic>BRCA1<\/jats:italic>, <jats:italic>BRCA2<\/jats:italic>, and <jats:italic>TP53<\/jats:italic>, prophylactic mastectomy is often recommended and radiation therapy avoided when possible for those with Li-Fraumeni syndrome (LFS). For germline PV carriers in more moderate-risk genes such as PALB2, <jats:italic>ATM<\/jats:italic>, and <jats:italic>CHEK2<\/jats:italic>, annual breast MRI is recommended and prophylactic mastectomies considered for those with significant family histories. Detection of PVs in cancer susceptibility genes can also lead to recommendations for other prophylactic surgeries (e.g., salpingo-oophorectomy) and increased surveillance for other cancers. Therefore, recognizing when a PV is somatic rather than germline and distinguishing somatic mosaicism from clonal hematopoiesis (CH) is essential. Mutational events that occur at a post-zygotic stage are somatic and will only be present in tissues derived from the mutated cell, characterizing classic mosaicism. Clonal hematopoiesis is a form of mosaicism restricted to the hematopoietic compartment.<\/jats:p>\n              <jats:p>Among the genes in multi-gene panels used for germline testing of breast cancer patients, the detection of a PV with low MAF occurs most often in <jats:italic>TP53<\/jats:italic>, though has been reported in other breast cancer susceptibility genes. Distinguishing a germline <jats:italic>TP53<\/jats:italic> PV (LFS) from a somatic PV (<jats:italic>TP53<\/jats:italic> mosaicism or CH) has enormous implications for breast cancer patients and their relatives.<\/jats:p>\n              <jats:p>We review how to evaluate a PV with low MAF. The identification of the PV in another tissue confirms mosaicism. Older age, exposure to chemotherapy, radiation, and tobacco are known risk factors for CH, as is the absence of a LFS-related cancer in the setting of a <jats:italic>TP53<\/jats:italic> PV with low MAF. The ability to recognize and understand the implications of somatic PVs, including somatic mosaicism and CH, enables optimal personalized care of breast cancer patients.<\/jats:p>","DOI":"10.1186\/s13058-019-1193-1","type":"journal-article","created":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T09:04:12Z","timestamp":1568797452000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":79,"title":["Li-Fraumeni syndrome: not a straightforward diagnosis anymore\u2014the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis"],"prefix":"10.1186","volume":"21","author":[{"given":"Felipe","family":"Batalini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellie G.","family":"Peacock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Stobie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy","family":"Garber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey N.","family":"Weitzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1422-3734","authenticated-orcid":false,"given":"Nadine M.","family":"Tung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,18]]},"reference":[{"issue":"1","key":"1193_CR1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/ng853","volume":"31","author":"Paul D.P. Pharoah","year":"2002","unstructured":"Pharoah PDP, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BAJ. Polygenic susceptibility to breast cancer and implications for prevention. Nature genetics 2002 31:1. Nat Publ Group; 2002;31:33\u201336.","journal-title":"Nature Genetics"},{"key":"1193_CR2","first-page":"232","volume":"48","author":"EB Claus","year":"1991","unstructured":"Claus EB, Risch N, Thompson WD. Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet. 1991;48:232\u201342.","journal-title":"Am J Hum Genet"},{"key":"1193_CR3","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1073\/pnas.85.9.3044","volume":"85","author":"B Newman","year":"1988","unstructured":"Newman B, Austin MA, Lee M, King MC. Inheritance of human breast cancer: evidence for autosomal dominant transmission in high-risk families. PNAS Natl Acad Sci. 1988;85:3044\u20138.","journal-title":"PNAS Natl Acad Sci"},{"key":"1193_CR4","doi-asserted-by":"publisher","first-page":"689","DOI":"10.2217\/fon.09.29","volume":"5","author":"M Ghoussaini","year":"2009","unstructured":"Ghoussaini M, Pharoah PD. Polygenic susceptibility to breast cancer: current state-of-the-art. Future Oncol. 2009;5:689\u2013701.","journal-title":"Future Oncol"},{"key":"1193_CR5","unstructured":"Group ABCS. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. British Journal of Cancer. Nat Publ Group; 2000;83:1301\u20131308."},{"issue":"4","key":"1193_CR6","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1373\/clinchem.2015.249623","volume":"62","author":"TF Beck","year":"2016","unstructured":"Beck TF, Mullikin JC, Program OBOTNCS, Biesecker LG. Systematic evaluation of Sanger validation of NextGen sequencing variants. Clin Chem. 2016;62(4):647\u201354.","journal-title":"Clin Chem"},{"issue":"8","key":"1193_CR7","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/gim.2017.196","volume":"20","author":"Jeffrey N Weitzel","year":"2017","unstructured":"Weitzel JN, Chao EC, Nehoray B, Van Tongeren LR, LaDuca H, Blazer KR, et al. Somatic TP53 variants frequently confound germ-line testing results. Genetics in medicine 2018 20:8. Nat Publ Group; 2018;20:809\u2013816.","journal-title":"Genetics in Medicine"},{"key":"1193_CR8","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s12885-015-1224-y","volume":"15","author":"T Judkins","year":"2015","unstructured":"Judkins T, Leclair B, Bowles K, Gutin N, Trost J, McCulloch J, et al. Development and analytical validation of a 25-gene next generation sequencing panel that includes the BRCA1 and BRCA2 genes to assess hereditary cancer risk. BMC Cancer. 2015;15:215.","journal-title":"BMC Cancer"},{"key":"1193_CR9","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood.V126.23.16.16","volume":"126","author":"DP Steensma","year":"2015","unstructured":"Steensma DP, Bejar R, Jaiswal S, Lindsley RC, Sekeres MA, Hasserjian RP, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015;126:16.","journal-title":"Blood"},{"key":"1193_CR10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.cancergen.2017.01.002","volume":"211","author":"B Coffee","year":"2017","unstructured":"Coffee B, Cox HC, Kidd J, Sizemore S, Brown K, Manley S, et al. Detection of somatic variants in peripheral blood lymphocytes using a next generation sequencing multigene pan cancer panel. Cancer Genet. 2017;211:5\u20138.","journal-title":"Cancer Genet"},{"key":"1193_CR11","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1001\/jamaoncol.2018.2297","volume":"4","author":"RN Ptashkin","year":"2018","unstructured":"Ptashkin RN, Mandelker DL, Coombs CC, Bolton K, Yelskaya Z, Hyman DM, et al. Prevalence of clonal hematopoiesis mutations in tumor-only clinical genomic profiling of solid tumors. JAMA Oncol. 2018;4:1589\u201393.","journal-title":"JAMA Oncol"},{"key":"1193_CR12","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1200\/JCO.2015.65.0747","volume":"34","author":"N Tung","year":"2016","unstructured":"Tung N, Lin NU, Kidd J, Allen BA, Singh N, Wenstrup RJ, et al. Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer. J Clin Oncol. 2016;34:1460\u20138.","journal-title":"J Clin Oncol"},{"key":"1193_CR13","doi-asserted-by":"publisher","first-page":"3556","DOI":"10.1245\/s10434-018-6581-8","volume":"25","author":"KA Theobald","year":"2018","unstructured":"Theobald KA, Susswein LR, Marshall ML, Roberts ME, Mester JL, Speyer D, et al. Utility of expedited hereditary cancer testing in the surgical management of patients with a new breast cancer diagnosis. Ann Surg Oncol. 2018;25:3556\u201362.","journal-title":"Ann Surg Oncol"},{"key":"1193_CR14","unstructured":"National Comprehensive Cancer Network. Genetic\/familial high-risk assessment: breast and ovarian (version 3.2019). \n                    https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_screening.pdf\n                    \n                  . Accessed 5 Sept 2019."},{"issue":"6","key":"1193_CR15","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"Mark Robson","year":"2017","unstructured":"Robson M, Im S-A, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523\u201333.","journal-title":"New England Journal of Medicine"},{"key":"1193_CR16","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa1802905","volume":"379","author":"JK Litton","year":"2018","unstructured":"Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gon\u00e7alves A, Lee K-H, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379:753\u201363.","journal-title":"N Engl J Med"},{"issue":"6","key":"1193_CR17","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1200\/JCO.18.01631","volume":"37","author":"Peter D. Beitsch","year":"2019","unstructured":"Beitsch PD, Whitworth PW, Hughes K, Patel R, Rosen B, Compagnoni G, et al. Underdiagnosis of hereditary breast cancer: are genetic testing guidelines a tool or an obstacle? J Clin Oncol. 2019;37(6):453\u201360.","journal-title":"Journal of Clinical Oncology"},{"key":"1193_CR18","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1245\/s10434-018-6621-4","volume":"25","author":"S Yang","year":"2018","unstructured":"Yang S, Axilbund JE, O\u2019Leary E, Michalski ST, Evans R, Lincoln SE, et al. Underdiagnosis of hereditary breast and ovarian cancer in Medicare patients: genetic testing criteria miss the mark. Ann Surg Oncol. 2018;25:2925\u201331.","journal-title":"Ann Surg Oncol"},{"key":"1193_CR19","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.tig.2015.03.013","volume":"31","author":"IM Campbell","year":"2015","unstructured":"Campbell IM, Shaw CA, Stankiewicz P, Lupski JR. Somatic mosaicism: implications for disease and transmission genetics. Trends Genet. 2015;31:382\u201392.","journal-title":"Trends Genet"},{"key":"1193_CR20","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.tig.2015.07.004","volume":"32","author":"IM Campbell","year":"2016","unstructured":"Campbell IM, Shaw CA, Stankiewicz P, Lupski JR. Erratum to: somatic mosaicism: implications for disease and transmission genetics. Trends Genet. 2016;32:138.","journal-title":"Trends Genet"},{"key":"1193_CR21","unstructured":"Jacobs KB, Yeager M, Zhou W, Wacholder S, Wang Z, Rodriguez-Santiago B, et al. Detectable clonal mosaicism and its relationship to aging and cancer. Nature genetics 2002 31:1. Nat Publ Group; 2012;44:651\u2013658."},{"issue":"26","key":"1193_CR22","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","volume":"371","author":"Siddhartha Jaiswal","year":"2014","unstructured":"Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371:2488\u201398.\u00a0","journal-title":"New England Journal of Medicine"},{"key":"1193_CR23","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1038\/nm.3733","volume":"20","author":"M Xie","year":"2014","unstructured":"Xie M, Lu C, Wang J, McLellan MD, Johnson KJ, Wendl MC, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med. 2014;20:1472\u20138.","journal-title":"Nat Med"},{"issue":"26","key":"1193_CR24","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","volume":"371","author":"Giulio Genovese","year":"2014","unstructured":"Genovese G, K\u00e4hler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371:2477\u201387.","journal-title":"New England Journal of Medicine"},{"key":"1193_CR25","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nature12634","volume":"502","author":"C Kandoth","year":"2013","unstructured":"Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502:333\u20139.","journal-title":"Nature"},{"key":"1193_CR26","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/nrc.2016.112","volume":"17","author":"AS Sperling","year":"2017","unstructured":"Sperling AS, Gibson CJ, Ebert BL. The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia. Nat Rev Cancer. 2017;17:5\u201319.","journal-title":"Nat Rev Cancer"},{"key":"1193_CR27","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/nature11725","volume":"493","author":"E Ruark","year":"2013","unstructured":"Ruark E, Snape K, Humburg P, Loveday C, Bajrami I, Brough R, et al. Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. Nature. 2013;493:406\u201310.","journal-title":"Nature"},{"key":"1193_CR28","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1001\/jamaoncol.2015.6053","volume":"2","author":"EM Swisher","year":"2016","unstructured":"Swisher EM, Harrell MI, Norquist BM, Walsh T, Brady M, Lee M, et al. Somatic mosaic mutations in PPM1D and TP53 in the blood of women with ovarian carcinoma. JAMA Oncol. 2016;2:370\u20132.","journal-title":"JAMA Oncol"},{"issue":"3","key":"1193_CR29","doi-asserted-by":"publisher","first-page":"374-382.e4","DOI":"10.1016\/j.stem.2017.07.010","volume":"21","author":"Catherine C. Coombs","year":"2017","unstructured":"Coombs CC, Zehir A, Devlin SM, Kishtagari A, Syed A, Jonsson P, et al. Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes. Cell Stem Cell; 2017;21:374\u20134.","journal-title":"Cell Stem Cell"},{"issue":"23","key":"1193_CR30","doi-asserted-by":"publisher","first-page":"5918","DOI":"10.1158\/1078-0432.CCR-18-1201","volume":"24","author":"CC Coombs","year":"2018","unstructured":"Coombs CC, Gillis NK, Tan X, Berg JS, Ball MC, Balasis ME, et al. Identification of clonal hematopoiesis mutations in solid tumor patients undergoing unpaired next-generation sequencing assays. Clin Cancer Res. 2018;24(23):5918\u201324.","journal-title":"Clin Cancer Res"},{"key":"1193_CR31","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1056\/NEJMra1706174","volume":"379","author":"RB Corcoran","year":"2018","unstructured":"Corcoran RB, Chabner BA. Application of cell-free DNA analysis to cancer treatment. N Engl J Med. 2018;379:1754\u201365.","journal-title":"N Engl J Med"},{"key":"1193_CR32","doi-asserted-by":"publisher","first-page":"eaan2415","DOI":"10.1126\/scitranslmed.aan2415","volume":"9","author":"J Phallen","year":"2017","unstructured":"Phallen J, Sausen M, Adleff V, Leal A, Hruban C, White J, et al. Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med. 2017;9:eaan2415.","journal-title":"Sci Transl Med"},{"issue":"18","key":"1193_CR33","doi-asserted-by":"publisher","first-page":"4437","DOI":"10.1158\/1078-0432.CCR-18-0143","volume":"24","author":"Y Hu","year":"2018","unstructured":"Hu Y, Ulrich B, Supplee J, Kuang Y, Lizotte PH, Feeney N, et al. False positive plasma genotyping due to clonal hematopoiesis. Clin Cancer Res. 2018;24(18):4437\u201343.","journal-title":"Clin Cancer Res"},{"key":"1193_CR34","first-page":"3371","volume":"129","author":"L Malcovati","year":"2017","unstructured":"Malcovati L, Gall\u00ec A, Travaglino E, Ambaglio I, Rizzo E, Molteni E, et al. Clinical significance of somatic mutation in unexplained blood cytopenia. Blood Am Soc Hematol. 2017;129:3371\u20138.","journal-title":"Blood Am Soc Hematol"},{"key":"1193_CR35","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1200\/JCO.18.00331","volume":"37","author":"KL Bolton","year":"2019","unstructured":"Bolton KL, Gillis NK, Coombs CC, Takahashi K, Zehir A, Bejar R, et al. Managing clonal hematopoiesis in patients with solid tumors. J Clin Oncol. 2019;37:7\u201311.","journal-title":"J Clin Oncol"},{"key":"1193_CR36","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1200\/JCO.2014.59.5728","volume":"33","author":"G Bougeard","year":"2015","unstructured":"Bougeard G, Renaux-Petel M, Flaman J-M, Charbonnier C, Fermey P, Belotti M, et al. Revisiting Li-Fraumeni syndrome from TP53 mutation carriers. J Clin Oncol. 2015;33:2345\u201352.","journal-title":"J Clin Oncol"},{"key":"1193_CR37","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1002\/cncr.26377","volume":"118","author":"AM Bertrandt","year":"2012","unstructured":"Bertrandt AM, Bojadzieva J, Ready KJ, Obeid E, Liu DD, Barrera AMG, et al. Early onset HER2-positive breast cancer is associated with germline TP53 mutations. Cancer. 2012;118:908\u201313.","journal-title":"Cancer"},{"key":"1193_CR38","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s10689-010-9415-9","volume":"10","author":"A Ferrarini","year":"2011","unstructured":"Ferrarini A, Auteri-Kaczmarek A, Pica A, Boesch N, Heinimann K, Sch\u00e4fer SC, et al. Early occurrence of lung adenocarcinoma and breast cancer after radiotherapy of a chest wall sarcoma in a patient with a de novo germline mutation in TP53. Familial Cancer. 2011;10:187\u201392.","journal-title":"Familial Cancer"},{"key":"1193_CR39","doi-asserted-by":"publisher","first-page":"939","DOI":"10.6004\/jnccn.2012.0097","volume":"10","author":"E Henry","year":"2012","unstructured":"Henry E, Villalobos V, Million L, Jensen KC, West R, Ganjoo K, et al. Chest wall leiomyosarcoma after breast-conservative therapy for early-stage breast cancer in a young woman with Li-Fraumeni syndrome. J Natl Compr Cancer Netw. 2012;10:939\u201342.","journal-title":"J Natl Compr Cancer Netw"},{"key":"1193_CR40","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/1748-717X-5-104","volume":"5","author":"S Heymann","year":"2010","unstructured":"Heymann S, Delaloge S, Rahal A, Caron O, Fr\u00e9bourg T, Barreau L, et al. Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome. Radiat Oncol. 2010;5:104.","journal-title":"Radiat Oncol"},{"key":"1193_CR41","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/ijc.1021","volume":"96","author":"JM Limacher","year":"2001","unstructured":"Limacher JM, Frebourg T, Natarajan-Ame S, Bergerat JP. Two metachronous tumors in the radiotherapy fields of a patient with Li-Fraumeni syndrome. Int J Cancer. 2001;96:238\u201342.","journal-title":"Int J Cancer"},{"key":"1193_CR42","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.clon.2007.05.001","volume":"19","author":"A Salmon","year":"2007","unstructured":"Salmon A, Amikam D, Sodha N, Davidson S, Basel-Vanagaite L, Eeles RA, et al. Rapid development of post-radiotherapy sarcoma and breast cancer in a patient with a novel germline \u201cde-novo\u201d TP53 mutation. Clin Oncol. 2007;19:490\u20133.","journal-title":"Clin Oncol"},{"key":"1193_CR43","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1093\/jnci\/djy001","volume":"110","author":"HQ Rana","year":"2018","unstructured":"Rana HQ, Gelman R, LaDuca H, McFarland R, Dalton E, Thompson J, et al. Differences in TP53 mutation carrier phenotypes emerge from panel-based testing. J Natl Cancer Inst. 2018;110:863\u201370.","journal-title":"J Natl Cancer Inst"},{"key":"1193_CR44","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1136\/jmedgenet-2017-104976","volume":"55","author":"M Renaux-Petel","year":"2018","unstructured":"Renaux-Petel M, Charbonnier F, Th\u00e9ry J-C, Fermey P, Lienard G, Bou J, et al. Contribution of de novo and mosaic TP53 mutations to Li-Fraumeni syndrome. J Med Genet. 2018;55:173\u201380.","journal-title":"J Med Genet"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-019-1193-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13058-019-1193-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-019-1193-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T23:37:25Z","timestamp":1600299445000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-019-1193-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,18]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1193"],"URL":"https:\/\/doi.org\/10.1186\/s13058-019-1193-1","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,18]]},"assertion":[{"value":"2 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There was no involvement of human participants\/subjects, human data, or human tissue.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The manuscript does not contain any individual person\u2019s data in any form.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"NT reported research funding from AstraZeneca. JG reported consulting for Helix Genetics, Konica-Minolta, and Novartis (spouse) and research support from Invitae, Ambry, and AstraZeneca. FB, EP, LS, AR, and JW declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"107"}}